Sign In
Buy ALT
$2.87
-0.0300 (-1.03%)
At Close: Jun 03, 2026
Levi & Korsinsky Notifies Shareholders of Altimmune, Inc. (ALT) of a Class Action Lawsuit and an Upcoming Deadline
05:55am, Monday, 13'th May 2024
NEW YORK, NY / ACCESSWIRE / May 13, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow
NEW YORK, NY / ACCESSWIRE / May 13, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow
Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT
10:00pm, Sunday, 12'th May 2024
NEW YORK, NY / ACCESSWIRE / May 12, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
11:33am, Tuesday, 07'th May 2024
Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.
Altimmune to Participate at Two Upcoming Conferences
07:30am, Wednesday, 01'st May 2024
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
06:33am, Wednesday, 24'th Apr 2024
Investors continue to search for the next big weight loss drug stocks following the success of Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ). So-called GLP-1 receptor agonists represent a funda
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
06:05am, Monday, 22'nd Apr 2024
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic
Buy Altimmune's Potential Market Disruption With Pemvidutide
12:02pm, Friday, 12'th Apr 2024
Altimmune is a clinical-stage biopharmaceutical company focused on developing peptide-based treatments for obesity and liver diseases. Their lead drug candidate, Pemvidutide, targets glucagon-like pep
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
12:24pm, Thursday, 11'th Apr 2024
Biotech stocks can offer some of the most explosive, exciting opportunities on the market. That is, if you find the right one.
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
06:08am, Tuesday, 09'th Apr 2024
Altimmune Inc. NASDAQ: ALT is a clinical-stage biotechnology company specializing in treating liver disease and obesity. Their lead drug, Pemvidutide, has garnered much attention as a GLP-1/glucagon d
The 3 Best Biotech Stocks to Buy in April 2024
09:09pm, Monday, 01'st Apr 2024
Right now, biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April. All of this is thanks to new innovation, millions of ret
Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade
01:01pm, Friday, 29'th Mar 2024
Altimmune (ALT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place
07:50pm, Wednesday, 27'th Mar 2024
Positive results achieved from phase 2 MOMENTUM study, whereby patients not only achieved significant weight loss over a 48-week period with pemvidutide but also had lean mass preservation. It is said
Altimmune says weight loss drug minimized muscle loss in trial results that may set it apart
02:30pm, Wednesday, 27'th Mar 2024
The results are a sign that Altimmune can address an area of concern around weight loss drugs, which is that they shrink critical muscle mass.
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
07:30am, Wednesday, 20'th Mar 2024
GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 20
